178 related articles for article (PubMed ID: 23171475)
1. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system.
Nie ZL; Pan YQ; He BS; Gu L; Chen LP; Li R; Xu YQ; Gao TY; Song GQ; Hoffman AR; Wang SK; Hu JF
Mol Cancer; 2012 Nov; 11():86. PubMed ID: 23171475
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting.
Sun H; Pan Y; He B; Deng Q; Li R; Xu Y; Chen J; Gao T; Ying H; Wang F; Liu X; Wang S
Int J Oncol; 2015 Apr; 46(4):1759-67. PubMed ID: 25625919
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting.
Pan Y; He B; Lirong Z; Nie Z; Chen L; Gu L; Hoffman AR; Wang S; Hu J
Oncol Rep; 2013 Oct; 30(4):1814-22. PubMed ID: 23900345
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system.
Pan Y; He B; Chen J; Sun H; Deng Q; Wang F; Ying H; Liu X; Lin K; Peng H; Xie H; Wang S
Int J Oncol; 2015 Nov; 47(5):1881-9. PubMed ID: 26397886
[TBL] [Abstract][Full Text] [Related]
5. [Effect of recombinant adenovirus Ad-DT-A in targeted therapy for malignant cancer cell lines with loss of IGF2 imprinting].
Pan YQ; He BS; Zhu C; Qu LL; Xu XF; Wang SK
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):816-21. PubMed ID: 22335945
[TBL] [Abstract][Full Text] [Related]
6. Targeted tumor gene therapy based on loss of IGF2 imprinting.
Pan Y; He B; Li T; Zhu C; Zhang L; Wang B; Xu Y; Qu L; Hoffman AR; Wang S; Hu J
Cancer Biol Ther; 2010 Aug; 10(3):290-8. PubMed ID: 20592487
[TBL] [Abstract][Full Text] [Related]
7. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
8. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
9. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.
Cui H; Onyango P; Brandenburg S; Wu Y; Hsieh CL; Feinberg AP
Cancer Res; 2002 Nov; 62(22):6442-6. PubMed ID: 12438232
[TBL] [Abstract][Full Text] [Related]
10. Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene.
Cruz-Correa M; Zhao R; Oviedo M; Bernabe RD; Lacourt M; Cardona A; Lopez-Enriquez R; Wexner S; Cuffari C; Hylind L; Platz E; Cui H; Feinberg AP; Giardiello FM
Epigenetics; 2009 Feb; 4(2):114-8. PubMed ID: 19242102
[TBL] [Abstract][Full Text] [Related]
11. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
12. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
[TBL] [Abstract][Full Text] [Related]
13. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
15. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
16. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
17. Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.
Zhao X; Liu X; Wang G; Wen X; Zhang X; Hoffman AR; Li W; Hu JF; Cui J
Oncotarget; 2016 Aug; 7(32):51349-51364. PubMed ID: 27275535
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
[TBL] [Abstract][Full Text] [Related]
19. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer.
Yu DB; Zhong SY; Yang M; Wang YG; Qian QJ; Zheng S; Liu XY
Cancer Sci; 2009 Apr; 100(4):678-83. PubMed ID: 19298599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
